Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Irinotecan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    523 result(s) found for: Irinotecan. Displaying page 1 of 27.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-002134-14 Sponsor Protocol Number: 1.0 Start Date*: 2022-09-02
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study
    Medical condition: Patients with peritoneal carcinomatosis of colorectal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004576-22 Sponsor Protocol Number: IRI28 Start Date*: 2017-07-14
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002925-29 Sponsor Protocol Number: 200605 Start Date*: 2005-09-20
    Sponsor Name:University Childrens Hospital
    Full Title: Irinotecan singele drug treatment for children with refractory or relapsed hepatoblastoma
    Medical condition: Refractory or recurrent hepatoblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004471-13 Sponsor Protocol Number: PM1183-C-008-21 Start Date*: 2022-08-03
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps...
    Medical condition: Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002748-25 Sponsor Protocol Number: KFE19.17 Start Date*: 2019-10-11
    Sponsor Name:Department of Oncology, Odense Universitetshospital
    Full Title: Repurposing disulfiram as treatment for metastatic colorectal cancer An investigator initiated clinical phase II trial
    Medical condition: Metastatic, non-resectable and irinotecan-resistant colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001275-21 Sponsor Protocol Number: IriGen Start Date*: 2013-07-29
    Sponsor Name:Centre Jean Perrin
    Full Title: Phase II study: individualization of dosage of irinotecan in the FOLFIRI according to the genetic polymorphism of UGT1A1 in the first line treatment of metastatic colorectal cancer
    Medical condition: first line metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000317-36 Sponsor Protocol Number: 0646-025 Start Date*: 2012-06-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Can...
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003352-67 Sponsor Protocol Number: E7389-G000-213 Start Date*: 2017-05-08
    Sponsor Name:Eisai Ltd
    Full Title: A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors
    Medical condition: Phase 1: paediatric subjects with relapsed/refractory solid tumors (excluding CNS) Phase 2: paediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sar...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001116-22 Sponsor Protocol Number: 0646-004 Start Date*: 2007-10-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer
    Medical condition: metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010036 Colorectal carcinoma LLT
    9.1 10027477 Metastatic carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended) SE (Completed) LT (Completed) FI (Completed) FR (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005437-32 Sponsor Protocol Number: ERASE-TMZ Start Date*: 2021-03-10
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva...
    Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001170 Adenocarcinoma of colon stage II LLT
    21.0 100000004864 10001171 Adenocarcinoma of colon stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000758-20 Sponsor Protocol Number: DIV-SCLC-301 Start Date*: 2017-06-21
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
    Medical condition: relapsed or refractory small cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Completed) LT (Completed) FR (Completed) PL (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004806-28 Sponsor Protocol Number: C07-1 Start Date*: 2008-02-14
    Sponsor Name:GERCOR
    Full Title: An Open-label Phase II Clinical trial of Panitumumab in Combination with Irinotecan for Patients with Advanced Metastatic Colorectal Cancer without KRAS mutation (Wild type) in third line chemother...
    Medical condition: histologically confirmed Metastatic colorectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001126-15 Sponsor Protocol Number: CRICKET Start Date*: 2014-10-03
    Sponsor Name:G.O.N.O. (Gruppo Oncologico Nord Ovest)
    Full Title: A phase II single-arm study of cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing...
    Medical condition: metastatic colonrectal cancer KRAS, NRAS and BRAF wild type.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004166-18 Sponsor Protocol Number: FFCD1201 Start Date*: 2013-01-09
    Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD)
    Full Title: Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter ...
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001362-14 Sponsor Protocol Number: EMR200020-034 Start Date*: 2005-06-16
    Sponsor Name:Merck KGaA
    Full Title: Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic...
    Medical condition: Epidermal Growth Factor Receptor (EGFR) expressing, metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052362 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003160-19 Sponsor Protocol Number: ASL608LIOM01 Start Date*: 2008-09-07
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETR...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001167 Adenocarcinoma of colon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000649-39 Sponsor Protocol Number: EMR62202-502 Start Date*: 2004-12-01
    Sponsor Name:Merck KGaA
    Full Title: A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalat...
    Medical condition: Metastatic colorectal cancer refractory to irinotecan treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002095-40 Sponsor Protocol Number: B2151005 Start Date*: 2014-06-12
    Sponsor Name:Pfizer Inc.,235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER
    Medical condition: Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10018065 - General disorders and administration site conditions 10069755 K-ras gene mutation PT
    17.0 10018065 - General disorders and administration site conditions 10071972 N-ras gene mutation PT
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002374-46 Sponsor Protocol Number: UC-0110/1807 Start Date*: 2018-11-09
    Sponsor Name:UNICANCER
    Full Title: A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas.
    Medical condition: Patients aged ≥18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000987-11 Sponsor Protocol Number: 2012/409 Start Date*: 2012-07-02
    Sponsor Name:Anni Ravnbek Jensen
    Full Title: DEBIRI-TACE (DRUG ELUTING BEAD med IRINOTECAN-TRANS ARTERIEL CHEMO EMBOLIZATION) Intrahepatic chemoembolization with irinotecan-containing DC-BEADS combined with systemic chemotherapy and bevac...
    Medical condition: Metastatic colorectal cancer with metastasis confined to the liver
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:38:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA